Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Intrapatient Dose Escalation of Sorafenib in First-Line Metastatic Renal Cell Carcinoma
2007-004875-21Phase 2Completed
- Sponsor
- Bayer
- Start
- Dec 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sorafenib in metastatic renal cell carcinoma (mRCC), sponsored by Bayer. Started Dec 2007; status: completed.
02
Drugs
sorafenib
03
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on 2007-004875-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004875-21.